Months after the launch of the COVID-19 immunization, new data from Pfizer suggests that its vaccine was 100 percent effective in preventing severe cases of coronavirus, with the drug’s effects lasting more than six months. The new study was based on Pfizer-BioNTech’s original immunization research, following participants who had been injected with BNT162b2 to see who had contracted COVID-19.
As the initial results – which helped BNT162b2 to obtain an emergency use authorization (USA) from the US Food and Drug Administration (FDA) – indicated, the candidate vaccine is 100% effective in preventing than the US Centers for Control and Disease Prevention (CDC) defines it as “serious illness”. Coronavirus cases lead to hospitalization or even death.
As for the general cases of COVID-19, BNT162b2 has now shown 95.3 percent effectiveness. This is measured from seven days to up to six months after the second dose. Like Moderna’s vaccine, Pfizer-BioNTech requires two doses – separated by about 3-4 weeks – to be most effective.
In total, pharmaceutical companies said today, BNT162b2 is 91.3 percent effective against COVID-19. This is based on 927 confirmed cases of coronavirus as of March 13, 2021. 46,307 participants were involved in the study; of the confirmed cases, 850 were in the placebo group that did not receive the vaccine.
77 cases were of individuals who received the vaccine, but still received COVID-19. However, none were classified as a serious case according to the CDC definition, although one was in accordance with the FDA definition.
As for the six-month outcome, it appears to be more about how long the study has run than a final figure of how long immunity actually lasts. Of the trial participants, more than 12,000 vaccinees received the vaccines six months or more ago.
The data also indicate that the Pfizer-BioNTech vaccine is effective against South Africa’s COVID-19 variant, pharmaceutical companies confirmed. In addition, there is also good news for concerns about side effects.
“No serious safety concerns were seen in trial participants until six months after the second dose,” said Pfizer-BioNTech today. She plans to send her data for peer review and possible publication, as well as part of an eventual Biological License Application for BNT162b2. This will initiate the process of obtaining full approval of the drug by the FDA, instead of its use during the pandemic according to emergency rules
Earlier this week, Pfizer-BioNTech confirmed that it was testing the vaccine with children and adolescents. One study, which looked at participants aged 12-15 years, found 100 percent effectiveness and a “robust antibody response” among the immunized group. Similar studies are underway with younger age groups.